SAN DIEGO — Inovio Biomedical Corp. announced Feb. 8 additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine trial.
VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus types 16 and 18 and is delivered via in vivo electroporation.
Similar to previously reported data from the initial lowest dose cohort of this Phase I trial, the vaccine was found to be generally safe and well tolerated. While previously reported data showed significant cellular and humoral immune responses, data from this second, intermediate dose group highlighted a significantly increased and dose-related immune response specific to the antigens targeted by the vaccine.
"Analyses of the vaccinated subjects from the first two cohorts indicate that this vaccine is highly immunogenic, generating antigen-specific T-cell and antibody responses that are amongst the highest reported from any previous human studies of DNA vaccines," stated Dr. J. Joseph Kim, president and CEO.
"While recent HPV preventive vaccines have been successful in protecting against infections that may lead to cervical cancer, Inovio's therapeutic vaccine targets the millions of women already infected with HPV and is intended to treat pre-cancerous cells and cervical cancer caused by this virus. Current vaccines do not serve this group of women."